Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/27/16  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Michael G. Schlossmacher

Wrong Dr. Michael G. Schlossmacher?

Program In Neuroscience

Phone: (613) ***-**** ext. ****  
Ottawa Hospital Research Institute
501 Smyth
Ottawa , Ontario K1H 8L6

Company Description: The OHRI is one of the lead sites in Canada for the study of human reproductive health. Its research programs address important women's and infant health issues...   more

Employment History

Board Memberships and Affiliations


  • MD
  • M.D.
93 Total References
Web References
Ottawa researchers get $2.5 million to study genetic link among three chronic diseases - OHRI, 11 July 2014 [cached]
David Park and Michael Schlossmacher, to test an intriguing hypothesis: that there is a common immune system link among these three seemingly unrelated diseases, a gene called LRRK2, believed to regulate immune system function.
Dr. Michael Schlossmacher is a senior scientist at the Ottawa Hospital Research Institute and director of the MD/PhD Program at the uOttawa Faculty of Medicine.
Dopamine 2016 :: September, 2016 :: Vienna, Austria, 30 Dec 2015 [cached]
Speaker 2: Michael Schlossmacher (University of Ottawa, Canada)
Title to be announced
Ottawa Hospital Research Institute, 28 Nov 2012 [cached]
Dr. Michael Schlossmacher was recently awarded the Canada Research Chair in Parkinson Disease Ottawa Hospital Research Institute
Dr. Michael Schlossmacher was recently awarded the Canada Research Chair in Parkinson Disease
On December 7, 2006, Dr. Michael Schlossmacher was awarded a prestigious Canada Research Chair in Parkinson Disease. Dr. Schlossmacher joined the Ottawa Hospital Research Institute as a Scientist in the Neuroscience Program in August 2006. He is also an Associate Professor at the University of Ottawa (Division of Neurology, cross-appointed to the Department of Cellular and Molecular Medicine), and a neurologist at The Ottawa Hospital.
The goal of Dr. Schlossmacher's work as a physician-scientist is to contribute to the improved care of patients with neurodegenerative diseases. In 1988, a Fulbright Commission scholarship enabled Dr. Schlossmacher to visit Harvard University and undergo scientific training in Alzheimer disease under Dr. Dennis Selkoe.
After residency training in medicine in Vienna, Dr. Schlossmacher returned to Boston to become a neurologist. As of 2000, he focused his clinical practice and his research on Parkinson disease (at the Department of Neurology of Massachusetts General Hospital and at the Center for Neurologic Diseases at Brigham & Women's Hospital).
At the OHRI, Dr. Schlossmacher will be working closely with Dr. David Grimes, Dr. David Park, and other members of the Parkinson Research Consortium.
Dr. Schlossmacher's OHRI profile
Dr. Schlossmacher's Canada Research Chair profile
Dr. Schlossmacher's recently published review of the implications of Parkinson disease genetics
Home, 11 June 2009 [cached]
Parkinson research by uOttawa scientist Dr. Michael Schlossmacher and colleagues could lead to new treatments.
Canadians for Health Research - Les Canadiens pour la Recherche Medicale - Future Health - single article, 1 Jan 2007 [cached]
To date, there is no definitive test for Parkinson's disease (PD) but Michael Schlossmacher, Canada Research Chair and associate professor at uOttawa and The Ottawa Hospital, is hoping that he and his team can change that.
Schlossmacher believes that the level of alpha-synuclein in spinal fluid decreases as PD progresses. If he can prove it, the team will have created the first lab-based yardstick or "biomarker" for different stages of the disease.
"We urgently need something more objective than patients telling us, 'I can't get out of bed now' or doctors estimating the degree of stiffness in a patient's limb," says Schlossmacher.
Having arrived at uOttawa last year from Harvard University, Schlossmacher is delighted to be working in Canada where he receives generous support from the Canada Research Chair program and uOttawa's Parkinson's Research Consortium. However, he is now looking for additional funding to confirm his team's findings in more patients.
"Pharmaceutical companies have a vested interest in such a test," says Schlossmacher. "They are sorely in need of a reliable biomarker that demonstrates whether new drugs interfere with the process of the disease."
For drug companies, a diagnosis based on this test would cut the cost of clinical trials. It would prevent patients with related diseases from being accidentally included in clinical trials, distorting results and delaying the development of new therapies.
"Now we know what the culprit is and how to measure it," says Schlossmacher.
Other People with the name "Schlossmacher":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.